Compare Five Below Inc (FIVE) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Incyte Corporation — how do they compare? Five Below Inc trades at $214.5 (market cap $11.55B), while Incyte Corporation trades at $113.22 (market cap $22.85B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is more actively traded (1,927,029 versus 1,120,554). Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Incyte Corporation for 33 Days on average.
| FIVE | INCY | |
|---|---|---|
Market Cap | $11.55B | $22.85B |
Volume | 1,120,554 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $129.93 |
52-Week Low | $138.49 | $83.80 |
Typical Hold Time | 46 Days | 33 Days |
Enterprise Value | $12.40B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $213.30, up 4.44% today, with strong earnings beats in recent quarters and a bullish analyst consensus of 60% buy ratings. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600 million buyback and board appointments.
Outlook remains positive with revenue projected to grow to $5.3 billion in 2026 and net income margin improving to 11.65%. Risks include premium valuation (P/E 18.81) and execution pressure amid economic headwinds. The consensus price target of $298.44 suggests 40% upside potential from current levels.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
